香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8156) 截至二零二三年九月三十日止三個月之 第一季度業績公告 國藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本 公司及其附屬公司截至二零二三年九月三十日止三個月的未經審核綜合財務業績。本公 告列載本公司第一季度報告2023/2024的全文，並符合香港聯合交易所有限公司GEM證 券上市規則（「GEM上市規則」）中有關季度業績初步公告附載的相關資料要求。 承董事會命 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 執行董事 周偉華 香港，二零二三年十一月十四日 於本公告日期，董事會由執行董事周偉華先生、何錦堅先生及郭淑儀女士，非執行董事程彥杰 博士，以及獨立非執行董事劉斐先生、許東安先生及向碧倫先生組成。 本 ...

Business Development and Revenue - The company continues to develop its pandemic-oriented business and "Internet+" services, establishing a solid foundation for future growth[9] - "Internet+" services provided the main revenue source during the review period, with ongoing expansion into supply chain services for health products[10] - The company has successfully entered various platforms, including Douyin and Xiaodian, to offer one-stop product supply chain services[10] - Revenue from personal protective equipment (PPE) decreased due to reduced demand as the pandemic situation improved, prompting a resource reallocation towards health industry supply chain services[11] - Revenue from the "Internet+" supply chain services increased by 25% to HKD 37,100,000, compared to HKD 29,700,000 in the previous fiscal year[17] - The gross margin for "Internet+" supply chain services improved to 13%, up from 8% in the previous year[17] - Revenue from PPE decreased by 37% to HKD 5,700,000, down from HKD 9,100,000 year-on-year, with a gross margin of 12% compared to 26% previously[18] - The company is exploring new opportunities in the health industry, including production and distribution of health products, and has signed contracts with health product brands for supply chain services in China and Hong Kong[15] - The company has established a joint venture in China to develop distribution for traditional Chinese medicine and health products, which is now fully operational[15] Financial Performance - The company recorded revenue of HKD 42,800,000 for the year ended June 30, 2023, representing a 4% increase from HKD 41,000,000 in the same period of 2022[16] - Gross profit decreased to HKD 5,500,000, down 7% from HKD 5,900,000 year-on-year, primarily due to reduced income from personal protective equipment (PPE) and increased production costs[16] - The company reported a loss attributable to equity holders of HKD 10,600,000, an 88% decrease compared to a loss of HKD 88,000,000 in the previous year[16] Corporate Governance and Compliance - The company has adopted and complied with the GEM Listing Rules Appendix 15 Corporate Governance Code, with some deviations noted[43] - The roles of Chairman and CEO are currently held by executive directors, which the board believes benefits the group's business prospects and management[46] - The board is responsible for reviewing the group's financial performance and approving strategic plans, major investments, and risk management policies[49] - The company had three independent non-executive directors until May 15, 2023, but this number fell below the required minimum of three after resignations[50] - The company appointed an independent non-executive director on August 15, 2023, and another on September 15, 2023, to comply with GEM Listing Rules[50] - All independent non-executive directors have submitted annual confirmations of their independence as required by GEM Listing Rules[51] - The company provides regular updates to directors on business developments and encourages participation in relevant seminars for professional development[53] - The board of directors held a total of 9 meetings during the fiscal year ending June 30, 2023[54] - The audit committee conducted 5 meetings to review financial reporting and compliance procedures[59] - The company appointed Dr. Xu Dong'an to the audit committee on August 15, 2023, and Mr. Xiang Bilun on September 15, 2023, to comply with GEM listing rules[58] - The audit committee's main responsibilities include reviewing the company's financial information and internal control systems[59] - The company has committed to providing all relevant information to the board and committees in a timely manner[56] - The board of directors ensures compliance with all applicable rules and regulations during meetings[56] - The company has sought independent professional advice when necessary, with costs covered by the company[56] - The company has a clear structure for its board committees, including specific powers and responsibilities[57] Employee and Talent Management - The total employee cost for the year was approximately HKD 5,000,000, a significant decrease from HKD 19,000,000 in 2022, with 19 employees as of June 30, 2023, down from 32[31] - The company employed a total of 19 staff members as of June 30, 2023, with compensation policies based on performance and market trends[31] - The company has implemented internal training and development opportunities for employees, ensuring a healthy and safe work environment[83] - The company achieved a gender ratio of approximately 68% male to 32% female among staff, including senior management, as of June 30, 2023[71] - The board diversity policy was successfully implemented, achieving measurable targets including at least one director of a different gender and representation from multiple age groups[70] - The company reported zero work-related deaths and zero days lost due to work injuries for the years ending June 30, 2023, 2022, and 2021[181] - The percentage of trained employees increased for males to 26.00% in 2023 from 25.00% in 2022, while for females it rose to 5.00% from 0.00%[185] - Average training hours per employee remained at 1.00 hour for both male and female employees in 2023, consistent with 2022[186] Legal and Regulatory Issues - The company is facing uncertainties in its lottery-related business and will explore its prospects while making necessary adjustments[12] - The company is currently in negotiations regarding the extension of convertible bonds issued in 2014, with a principal amount of HKD 89,625,000, which are no longer convertible[27] - A liquidation petition was filed against the company on August 31, 2023, for the repayment of HKD 53,106,849 related to convertible bonds, with a hearing scheduled for November 15, 2023[32] - The company is actively seeking legal advice and considering all necessary actions to protect its legal rights regarding a potential court application for a confirmation order[34] - The company will keep shareholders and potential investors informed of any significant developments related to the petition and its potential adverse effects on the group's business and operations[34] - The company is facing a liquidation petition for the repayment of convertible bonds totaling HKD 53,106,849, with a court hearing scheduled for November 15, 2023[147] - The company is actively negotiating with the petitioner to seek an amicable resolution to the liquidation petition[149] Environmental and Social Responsibility - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are primarily from daily electricity consumption[157] - The company reported zero emissions of nitrogen oxides, sulfur oxides, and suspended particulate matter for the year ending June 30, 2023, compared to 2,794 grams, 9.41 grams, and 205.72 grams respectively for the previous year[158] - The company is committed to improving energy and resource efficiency to manage its greenhouse gas emissions[159] - The company has adopted responsible waste management policies to minimize waste generation and promote recycling[157] - The company recognizes the potential financial impacts of climate-related risks and is monitoring regulatory environments and product markets to ensure compliance[175] - Supplier selection is based on environmental and social standards, with regular assessments of supply chain management risks[189] Shareholder and Capital Management - The total issued share capital as of June 30, 2023, was 4,592,326,397 shares, with a recent issuance of 54,637,617 shares at a price of HKD 0.28 per share[25] - On August 25, 2023, shareholders approved a share consolidation, merging every 25 shares into 1 share with a new par value of HKD 0.3125, effective August 29, 2023[26] - The board of directors did not recommend any dividend for the year ended June 30, 2023, consistent with the previous year[87] - The company has adopted a dividend policy that considers factors such as earnings per share and financial condition[88] - The company confirmed it has maintained sufficient public float as per GEM listing rules[94] - The company has not purchased, sold, or redeemed any listed securities during the year ended June 30, 2023[101] Stock Options and Incentives - The company granted a total of 263,900,000 share options at an exercise price of HKD 0.04, effective from July 1, 2023, to June 30, 2028[141] - The total number of stock options granted under the old stock option plan is 178,850,000[128] - The exercise price for the stock options is set at HKD 0.33[128] - The total number of stock options outstanding as of June 30, 2023, for the top five individuals was 60,100,000 shares[136] - The total number of stock options outstanding as of June 30, 2023, for other grantees was 96,650,000 shares[136] - The stock options granted to directors include a total of 128,900,000, with a significant portion still available for future exercise[137] - The company has granted stock options to multiple directors and employees, with significant allocations to key personnel[128] - The stock options are part of the company's strategy to incentivize and retain talent[128] Market and Customer Relations - Sales to the top five customers accounted for approximately 61% of total sales, with the largest customer representing about 33%[85] - Purchases from the top five suppliers constituted around 86% of total procurement, with the largest supplier accounting for 59%[85] - The company has maintained a cooperative relationship with suppliers to effectively meet customer demands[84] - The company received no written complaints regarding product and service quality during the year, and has procedures in place to investigate and address any complaints[196] Risk Management - The company faced risks related to the "Internet+" service business, which is influenced by industry trends and future developments[82] - Demand for personal protective equipment (PPE) was directly affected by community health measures and the severity of the pandemic, impacting production and distribution[82] - The company incurred costs due to material, transportation, and labor law changes, which may affect profit margins in its "Internet+" services and PPE manufacturing[82] - The company is focused on expanding its market presence through innovative product development and strategic partnerships[138]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國 藥 科 技 股 份 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：8156） 截至二零二三年六月三十日止年度之 全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特色 GEM之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之中小型公司提供 一個上市的市場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周 詳之考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣之證券可能會較於聯交所主板買賣 之證券承受較大之市場波動風險，同時無法保證在GEM買賣之證券會有高流通量的市 場。 本公告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）之規定而刊載，旨在 提供有關國藥科技股份有限公司（「本公司」）的資料，本公司的董事（「董事」）願就本公告 ...

Financial Performance - For the three months ended March 31, 2023, the company reported revenue of HKD 4,729,000, a decrease of 82.0% compared to HKD 26,197,000 for the same period in 2022[3] - The gross profit for the nine months ended March 31, 2023, was HKD 3,951,000, remaining relatively stable compared to HKD 3,954,000 for the same period in 2022[3] - Operating loss for the three months ended March 31, 2023, was HKD 2,857,000, compared to an operating loss of HKD 8,061,000 for the same period in 2022[3] - The company recorded a net loss of HKD 6,178,000 for the three months ended March 31, 2023, an improvement from a net loss of HKD 9,869,000 in the same period of 2022[3] - Total comprehensive loss for the three months ended March 31, 2023, was HKD 6,477,000, compared to a total comprehensive loss of HKD 9,363,000 for the same period in 2022[5] - The company’s total revenue for the nine months ended March 31, 2023, was HKD 19,754,000, a decrease of 47.9% from HKD 37,927,000 in the same period of 2022[3] - Basic loss per share for the three months ended March 31, 2023, was HKD (0.14), compared to HKD (0.22) for the same period in 2022[5] - The basic and diluted loss per share for the three months ended March 31, 2023, was HKD 1.38, compared to a loss of HKD 2.21 for the same period in 2022[18] Revenue Sources - The company’s revenue from "Internet+" services (supply chain) for the nine months ended March 31, 2023, was HKD 15,011,000, down from HKD 28,687,000 in the same period of 2022[11] - The company’s revenue from personal protective equipment manufacturing and distribution for the nine months ended March 31, 2023, was HKD 4,743,000, down from HKD 7,698,000 in the same period of 2022[11] Other Income and Expenses - For the nine months ended March 31, 2023, the company reported a total other income of HKD 29,012,000, compared to HKD 15,269,000 for the same period in 2022, representing an increase of 90.5%[12] - The company recognized compensation income of HKD 16,458,000 from the sale of locked shares, having sold 534,000,000 shares during the period[12] - The pre-tax profit for the nine months ended March 31, 2023, was HKD 9,085,000, a significant improvement from a loss of HKD 23,413,000 in the same period of the previous year[18] - The cost of goods sold for the nine months ended March 31, 2023, was HKD 15,803,000, compared to HKD 6,537,000 for the same period in 2022, indicating a 142.5% increase[14] - The interest expense on convertible bonds for the nine months ended March 31, 2023, was HKD 7,241,000, down from HKD 10,192,000 in the same period of 2022, reflecting a decrease of 29.5%[14] Shareholder Information - Major shareholders include Frontend Investment Limited with 697,364,364 shares (15.19%) and Integrated Asset Management (Asia) Limited with 542,363,000 shares (11.81%)[35] - The total shareholding of Mr. Zhou Weihua is 43,800,000 shares, representing 0.95% of the company[31] Corporate Governance - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules Appendix 15, with some deviations noted[49] - The roles of Chairman and CEO are currently held by executive directors, which the board believes is beneficial for the company's business prospects and management[49] - The company has implemented a code of conduct for securities trading by directors, confirming compliance with the required standards during the nine months ended March 31, 2023[50] - The Audit Committee has been established and consists of three independent non-executive directors[51] - The Audit Committee is responsible for reviewing the company's annual reports, interim reports, and quarterly reports[51] - The Audit Committee has reviewed the unaudited performance for the nine months ending March 31, 2023, and confirmed compliance with applicable accounting standards[51] Stock Options - A total of 263,900,000 options were granted under the new share option scheme, with 77,000,000 options exercised as of March 31, 2023[45] - The exercise price for the options granted was set at HKD 0.04, with various vesting periods extending to June 30, 2028[45] - The total number of options available for employees under the scheme amounts to 131,000,000[45] - The total number of stock options granted under the old stock option plan as of March 31, 2023, is 178,850,000[43] - The total number of stock options exercised is 55,655,000, representing approximately 31% of the total options granted[43] - The total number of stock options for employees is 32,395,000, which accounts for about 18% of the total options granted[43] - The total number of stock options for consultants is 90,800,000, making up approximately 51% of the total options granted[43] - The exercise price for all stock options is set at HKD 0.33[43] - The stock options have various vesting periods, with some options expiring as early as February 28, 2021[43] - The company has a significant number of stock options that remain unexercised, indicating potential future dilution[43] - The stock options granted to directors total 55,655,000, which is 31% of the total options[43] - The company has seen a consistent approach to stock option grants, reflecting its strategy to incentivize key personnel[43] - The report indicates a structured approach to stock option management, with clear details on grants and exercises[43] Business Strategy - The company is actively exploring cooperation models with various platform operators in the "Internet+" business to expand market share[25] - The company has successfully entered the Douyin platform as a selected supplier for the "Global Preferred Import Supermarket"[26] - The demand for personal protective equipment has decreased, but the company continues to provide high-quality protective gear to customers[27] - The company is establishing a supply chain service network within the "Internet+" business through partnerships with logistics operators[26] - The company will continue to focus on the "Internet+" business model, leveraging years of experience and technology in supply chain services to expand its offerings[28] - The company is exploring opportunities in the health industry, including the production, distribution, and supply chain of health products, aiming to create new revenue sources[28] - The company plans to enhance sales and supply chain services for various health products across platforms in mainland China and Hong Kong[28] - The company is strengthening collaborations with platform operators to deepen partnerships in the "Internet+" services[28] - The company is actively seeking joint ventures with industry participants to develop "Internet+" solutions[28] Dividends - No dividend has been recommended for the nine months ending March 31, 2023, consistent with the previous year[29] Convertible Bonds - The company has issued convertible bonds that, upon conversion, will result in the issuance of up to 249,651,810 shares to Integrated Asset[36] - The maturity date of the convertible bonds has been extended from January 17, 2021, to January 17, 2022, with a conversion price adjusted from HKD 0.34 to HKD 0.221, allowing for the conversion of up to 405,542,986 shares[38] - The interest rate on the convertible bonds will increase to 10% per annum, payable annually[38] - As of the report date, Integrated Asset has not exercised any conversion rights on the company's shares since January 17, 2022, and no default notices have been received[39] - The company is in discussions with Integrated Asset regarding the renewal or further extension of the convertible bonds[39] Share Transactions - The company did not purchase, sell, or redeem any shares during the nine months ended March 31, 2023[46] - As of March 31, 2023, there were no interests held by directors, major shareholders, or their close associates in any business that directly or indirectly competes with the company[47] - The company has no provisions in its articles of association regarding pre-emptive rights for existing shareholders when new shares are issued[48]

香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 （於開曼群島註冊成立之有限公司） （股份代號：8156） 截至二零二三年三月三十一日止九個月之 第三季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）之特色 GEM之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之中小型公司提供 一個上市的市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周 詳之考慮後方作出投資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣之證券可能會較於聯交所主板買賣 之證券承受較大之市場波動風險，同時無法保證在GEM買賣之證券會有高流通量的市 場。 本公告的資料乃遵照GEM證券上市規則（「GEM上市規則」）之規定而刊載，旨在提供有 關國藥科技股份有限公司（「本公司」）的資料，本公司的董事（「董事」）願就本公告資料共 同及個別承擔全部責任。各董事在作出一切合理查詢後 ...

Financial Performance - For the six months ended December 31, 2022, the company's revenue was HKD 15,025,000, a 28.8% increase compared to HKD 11,730,000 for the same period in 2021[3]. - Gross profit for the six months ended December 31, 2022, was HKD 3,039,000, representing a 17.2% increase from HKD 2,593,000 in the previous year[3]. - Operating profit for the six months ended December 31, 2022, was HKD 19,771,000, compared to an operating loss of HKD 4,306,000 in the same period of 2021[3]. - The company reported a profit before tax of HKD 15,769,000 for the six months ended December 31, 2022, compared to a loss before tax of HKD 13,377,000 in the previous year[3]. - Basic earnings per share for the six months ended December 31, 2022, was HKD 0.34, compared to a loss per share of HKD 0.30 in the same period of 2021[5]. - Total comprehensive income for the six months ended December 31, 2022, was HKD 13,542,000, compared to a total comprehensive loss of HKD 13,334,000 in the previous year[5]. - The company reported a profit of HKD 15,769,000 for the six months ended December 31, 2022, compared to a loss of HKD 13,377,000 in the same period last year, representing a significant turnaround[9]. - Total revenue for the period was HKD 15,025,000, with HKD 10,825,000 from manufacturing and distribution services and HKD 4,200,000 from personal protective equipment[14]. - The company recognized other income of HKD 28,003,000 for the six months ended December 31, 2022, compared to HKD 15,265,000 in the same period of 2021[24]. - The profit attributable to equity holders for 2022 was HKD 15,400,000, a turnaround from a loss of HKD 13,500,000 in 2021[51]. Assets and Liabilities - As of December 31, 2022, the company's total assets were HKD 54,282,000, down from HKD 76,886,000 as of June 30, 2022[6]. - The company's net liabilities as of December 31, 2022, were HKD 156,436,000, an improvement from HKD 173,397,000 as of June 30, 2022[8]. - Total liabilities increased to HKD 210,718,000 as of December 31, 2022, compared to HKD 250,283,000 as of June 30, 2022[16][17]. - The company’s total liabilities decreased to HKD 156,436,000 as of December 31, 2022, from HKD 173,397,000 at the beginning of the period[9]. - Trade receivables amounted to HKD 84,808,000 as of December 31, 2022, down from HKD 117,907,000 as of June 30, 2022[34]. - The aging analysis of trade receivables shows that HKD 80,317,000 is overdue for more than one year as of December 31, 2022[35]. - Trade payables were reported at HKD 28,925,000 as of December 31, 2022, a decrease from HKD 54,589,000 as of June 30, 2022[36]. - The current liabilities were HKD 210,700,000, down from HKD 250,300,000 as of June 30, 2022[59]. - The group’s debt-to-asset ratio increased to 89% as of December 31, 2022, compared to 59% on June 30, 2022[59]. Cash Flow and Financing - The company reported cash and cash equivalents of HKD 7,283,000 as of December 31, 2022, compared to HKD 2,991,000 as of June 30, 2022[6]. - Operating cash flow improved to a net cash inflow of HKD 4,720,000, compared to an outflow of HKD 39,236,000 in the previous year[10]. - The company’s cash and cash equivalents increased to HKD 7,283,000 at the end of the period, up from HKD 4,015,000 a year earlier[10]. - The company incurred financing costs of HKD 4,002,000 during the period[14]. - Financing costs decreased to HKD 4,002,000 for the six months ended December 31, 2022, down from HKD 9,071,000 in the previous year[26]. - The company issued convertible bonds with a principal amount of HKD 89,625,000, with an adjusted conversion price of HKD 0.221 per share and an annual interest rate of 10%[43]. - The company issued a second series of convertible bonds with a principal amount of HKD 50,000,000, maturing on February 20, 2023, with an annual interest rate of 7%[44]. - The company plans to use the proceeds from the second series of convertible bonds for the development and promotion of its anti-counterfeiting business and general operating costs[44]. - The total outstanding balance of the convertible bonds at maturity was HKD 105,747,000, which includes the principal and accrued interest[43]. Operational Efficiency and Strategy - The company is focused on improving its operational efficiency and reducing losses through strategic initiatives and cost management[39]. - The company plans to continue expanding its "Internet+" services and enhance its supply chain solutions in the future[20]. - The company plans to explore opportunities in the health industry, including the production and distribution of health products, to create new revenue sources[57]. Shareholder Information - As of December 31, 2022, the total issued and paid-up shares were 4,592,326,000, with a nominal value of HKD 0.0125 per share[46]. - The total shares held by Mr. Zhou Weihua amounted to 43,800,000, representing 0.95% of the company[78]. - Mr. He Jinkian and Ms. Guo Shuyi each held 40,000,000 shares, accounting for 0.87% of the company[78]. - The largest shareholder, Frontend Investment Co., Ltd., held 697,364,364 shares, representing 15.19% of the company[82]. - Integrated Asset Management (Asia) Limited owned 542,363,000 shares, accounting for 11.81% of the company[82]. - Mr. Xie Shaohai held 310,650,000 shares, which is 6.76% of the company[82]. - No arrangements were made for directors or executives to benefit from purchasing the company's shares or bonds during the reporting period[80]. Corporate Governance - The company has adopted the GEM Listing Rules and complied with the corporate governance code, with no deviations reported as of December 31, 2022[107]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited results for the six months ended December 31, 2022, ensuring compliance with applicable accounting standards[109]. - The company has established a standard code of conduct for directors regarding securities trading, confirming compliance throughout the review period[108]. Stock Options and Employee Benefits - The new share option plan adopted on June 9, 2021, allows the board to grant options to qualified individuals to incentivize and reward their contributions[89]. - The total number of stock options granted under the old stock option plan as of December 31, 2022, is 178,850,000[93]. - The total number of stock options exercised as of December 31, 2022, is 55,655,000[92]. - The total number of stock options available for exercise as of December 31, 2022, is 90,800,000[93]. - The stock options granted to employees amount to 9,718,500 as of December 31, 2022[92]. - The stock options granted to directors total 55,655,000 as of December 31, 2022[92]. - The stock options have various vesting periods, with some expiring as late as December 31, 2022[93]. Events and Developments - The company has not identified any significant events affecting the group since the end of the reporting period[49]. - There were no significant events affecting the company after the reporting period ending December 31, 2022[76]. - The company has not reported any new product developments or market expansions in the provided documents[95]. - The company has not provided any future performance guidance or outlook in the available content[81].

Financial Performance - The company reported revenue of HKD 5,627,000 for the three months ended September 30, 2022, compared to HKD 1,679,000 for the same period in 2021, representing a 236% increase[3]. - Gross profit for the period was HKD 1,500,000, up from HKD 362,000 in the previous year, indicating a significant improvement in profitability[3]. - Operating profit for the quarter was HKD 6,309,000, compared to an operating loss of HKD 4,742,000 in the prior year[3]. - The company achieved a profit before tax of HKD 4,494,000, a turnaround from a loss of HKD 9,374,000 in the same quarter last year[3]. - The company reported a total comprehensive income of HKD 3,985,000 for the period, compared to a loss of HKD 9,612,000 in the prior year[5]. - The basic earnings per share for the period was HKD 0.10, compared to a loss per share of HKD 0.21 in the same quarter last year[5]. - The net profit attributable to equity holders was HKD 4,400,000, compared to a net loss of HKD 9,400,000 in the previous year[27]. Revenue Sources and Business Segments - The main business segments contributing to revenue included "Internet+" services and the manufacturing and distribution of personal protective equipment[8]. - The company sold 232,000,000 locked shares, generating compensation income of approximately HKD 9,800,000 during the quarter[15]. - Other income and gains totaled HKD 10,679,000, an increase from HKD 8,770,000 in the previous year, driven by compensation income from the sale of locked shares[12]. Cost Management - Selling and distribution expenses, along with administrative expenses, decreased by 62% to HKD 5,300,000 from HKD 13,900,000 in the previous year[27]. - Financing costs dropped by 61% to HKD 1,800,000 from HKD 4,600,000 in the previous year[27]. - The gross profit margin improved from 22% in the previous year to approximately 27%[27]. Strategic Initiatives - The company is actively exploring cooperation models with various platform operators to expand its "Internet+" business and market share[28]. - The company has successfully entered the Douyin platform's "Global Preferred Import Supermarket" as a selected supplier[28]. - The company obtained a wholesale license for traditional Chinese medicine, marking a step towards developing its cross-border supply chain business[28]. - The company focused on developing personal protective equipment manufacturing and distribution to meet current pandemic-related demands[29]. - The company is in discussions with major beauty brands and OTC drug manufacturers to expand product offerings on its platform[30]. - The company is exploring opportunities in the "Internet+" business model, including cross-border supply chain services and solutions in healthcare and wellness products[30]. - The company aims to create a one-stop business model by broadening supply channels and product combinations[30]. - The company continues to seek new revenue sources and development opportunities through industry collaborations[30]. Shareholder Information - As of September 30, 2022, major shareholders include Frontend Investment Holdings with 697,364,364 shares (15.37%) and Integrated Asset Management (Asia) Limited with 542,363,000 shares (11.95%)[37]. - The company has a total of 418,000,000 shares (9.21%) held by Guoyao Medicinal Materials Overseas Holdings Limited[37]. - The company’s directors and key executives hold a total of 7,400,000 shares, representing 0.16% of the company[33]. Stock Options and Equity Compensation - The old share option scheme was adopted on January 31, 2013, and was terminated on June 9, 2021[43]. - A new share option scheme was adopted on June 9, 2021, aimed at incentivizing qualified individuals for their contributions to the group[44]. - The total number of stock options granted under the old stock option plan as of September 30, 2022, is 55,655,000, with 34,455,000 options exercised and 21,200,000 options expired[46]. - The total number of stock options for other eligible participants is 90,800,000, with 61,850,000 options expired and 117,000,000 options remaining as of the same date[47]. - The exercise price for all stock options is set at HKD 0.33, with various vesting and exercise periods extending until December 31, 2022[46][47]. - The company has a total of 178,850,000 stock options, indicating a significant potential dilution of shares if all options are exercised[47]. - The stock options granted to directors and employees reflect a commitment to incentivize key personnel, with a total of 32,395,000 options allocated to employees[46]. - The company has not reported any stock options exercised during the reporting period, indicating a potential lack of liquidity or market conditions affecting option holders[46][47]. - The stock options are part of a broader strategy to retain talent and align employee interests with shareholder value[46]. - The company plans to continue monitoring market conditions to assess the viability of future stock option grants[47]. - The expiration of a significant number of options may impact future financial statements and shareholder equity[46][47]. - The company remains focused on strategic growth initiatives while managing its equity compensation plans effectively[46][47]. - As of September 30, 2022, the total number of stock options granted under the new stock option plan was 77,000,000[48]. - The exercise price for all stock options granted was HKD 0.25[48]. Compliance and Governance - The company has not adopted any new accounting standards that would significantly impact its financial reporting for the current period[6]. - The board does not recommend a dividend payment for the three months ending September 30, 2022, consistent with the previous year[31]. - The company has complied with the applicable code provisions of the GEM Listing Rules, except for the deviation regarding the roles of the Chairman and CEO being held by the same executive director[53]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the unaudited results for the three months ended September 30, 2022, and found them to comply with applicable accounting standards[58]. Convertible Bonds - The company has extended the maturity date of the convertible bonds to January 17, 2022, with a revised conversion price of HKD 0.221 per share, allowing for the conversion into a maximum of 405,542,986 shares[40]. - The interest rate on the convertible bonds has increased to 10% per annum, payable annually[40]. - As of the report date, the company has not received any default notices from Integrated Asset regarding the convertible bonds[41]. - The company is in discussions with Integrated Asset for the renewal or further extension of the convertible bonds[41]. Share Transactions - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the three months ended September 30, 2022[50].

Revenue and Business Performance - The "Internet+" services segment became the primary revenue source for the company, driven by the ongoing demand for epidemic prevention materials, resulting in a year-on-year increase in supply chain business revenue[9]. - The personal protective equipment (PPE) business experienced a contraction in revenue compared to the previous year, primarily due to the completion of a one-year local mask production subsidy program by the Hong Kong government[11]. - The group recorded revenue of HKD 41,000,000 for the year ended June 30, 2022, a decrease of 47% compared to HKD 77,800,000 in the same period of 2021[16]. - Gross profit for the same period was HKD 5,900,000, down 71% from HKD 20,900,000 in 2021[16]. - The group reported a loss attributable to equity holders of HKD 88,000,000, a 17% decrease from a loss of HKD 106,300,000 in the previous year[17]. - The "Internet+" supply chain services generated revenue of HKD 29,700,000, an increase of 138% from HKD 12,400,000 in the previous fiscal year[18]. - Revenue from personal protective equipment was HKD 9,100,000, a decrease of 86% from HKD 63,400,000 in the previous fiscal year[19]. Business Strategy and Development - The company has entered into commercial contracts with multiple enterprises in various provinces for innovative anti-counterfeiting products, covering industries such as tea and health food, with several batches of products delivered during the review period[10]. - The group plans to explore further opportunities in "Internet+" business development, particularly in healthcare-related platforms[15]. - The group signed service agreements with various platforms and brands to enhance its supply chain services, including partnerships with major beauty brands and a well-known skincare brand[14]. - The company is committed to developing and promoting its anti-counterfeiting business through the issuance of convertible bonds[39]. - The company is focused on expanding its e-commerce capabilities and enhancing its supply chain efficiency to meet growing market demands[52]. Financial Position and Capital Management - As of June 30, 2022, the group's bank balances and cash amounted to HKD 3,000,000, down from HKD 7,500,000 in 2021[26]. - Current assets totaled HKD 48,100,000, a slight decrease from HKD 49,600,000 in the previous year[26]. - Current liabilities were HKD 250,300,000, down from HKD 272,900,000 in 2021, resulting in a capital-to-debt ratio of 59% compared to 74% in the previous year[26]. - The company issued convertible bonds with a principal amount of HKD 89,625,000, which can be converted into a maximum of 150,000,000 shares at a conversion price of HKD 0.598 per share[31]. - The company issued a total of 263,602,941 shares upon full conversion of the convertible bonds at a revised conversion price of HKD 0.34 per share[34]. - The company has not received any default notices from bondholders and is in discussions for renewal or further extension of the convertible bonds[38]. Corporate Governance and Management - The company is committed to maintaining high levels of corporate governance and emphasizes the importance of a high-quality board composition, effective accountability systems, and a sound corporate culture to protect shareholder interests and enhance business growth[54]. - The board includes members with extensive academic and professional backgrounds, ensuring a diverse range of insights and expertise in decision-making processes[48][49]. - The independent non-executive directors play a crucial role in the audit and remuneration committees, ensuring transparency and accountability in financial reporting and executive compensation[48][49]. - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules Appendix 15, with some deviations noted[55]. - The board is responsible for reviewing the group's financial performance and approving strategic plans and major investments[59]. Risk Management and Compliance - The company faces risks related to the lottery industry trends and regulations, which could adversely affect its operations and financial performance[95]. - The company has a structured approach to the appointment and re-election of directors at the annual general meeting[62]. - The board conducts annual reviews of the effectiveness of the risk management and internal control systems[81]. - The company has a dedicated internal audit function to independently assess the adequacy and effectiveness of its risk management and internal control systems[82]. Environmental and Social Responsibility - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are the primary source of its carbon footprint[186]. - The company has adopted responsible waste management policies to minimize waste generation and promote recycling[186]. - Nitrogen oxides emissions decreased from 5,639.03 grams in 2021 to 2,794.00 grams in 2022, a reduction of approximately 50.5%[187]. - Carbon dioxide emissions from vehicle fuel combustion fell significantly from 16,936.45 kilograms in 2021 to 1,511.06 kilograms in 2022, a reduction of approximately 91.1%[189]. - The company aims to maintain the electricity consumption density per production line below 14.83 kilowatt-hours, achieving 12.82 kilowatt-hours in 2022[199].

Financial Performance - The company's revenue for the three months ended March 31, 2022, was HKD 26,197,000, a significant increase from HKD 12,918,000 in the same period last year, representing a growth of 102.4%[3] - For the nine months ended March 31, 2022, the total revenue was HKD 37,927,000, down from HKD 68,118,000 in the previous year, indicating a decline of 44.4%[3] - The gross profit for the three months ended March 31, 2022, was HKD 1,361,000, compared to HKD 3,649,000 in the same period last year, reflecting a decrease of 62.7%[3] - The operating loss for the nine months ended March 31, 2022, was HKD 12,367,000, an improvement from a loss of HKD 17,275,000 in the previous year, showing a reduction of 28.0%[3] - The company reported a net loss of HKD 9,869,000 for the three months ended March 31, 2022, compared to a net loss of HKD 17,623,000 in the same period last year, which is a 44.0% improvement[3] - The company’s basic loss per share for the three months ended March 31, 2022, was HKD 0.22, compared to HKD 0.40 in the same period last year, indicating a decrease of 45.0%[5] - The total comprehensive loss attributable to equity holders of the company for the nine months ended March 31, 2022, was HKD 23,051,000, compared to HKD 31,872,000 in the previous year, showing a reduction of 27.7%[5] - For the nine months ended March 31, 2022, the company reported a loss attributable to equity holders of HKD 23,413,000, compared to a loss of HKD 31,383,000 for the same period in 2021, representing a 25.4% improvement[16] - The basic and diluted loss per share for the nine months ended March 31, 2022, was HKD 5.22, compared to HKD 7.31 for the same period in 2021, indicating a decrease of 28.5%[16] - The net loss attributable to equity holders for 2022 was HKD 23,400,000, a 25% reduction from HKD 31,400,000 in 2021[24] Revenue Sources - The revenue from "Internet+" services (supply chain) for the three months ended March 31, 2022, was HKD 22,597,000, a substantial increase from HKD 4,358,000 in the same period last year, representing a growth of 419.5%[10] - The revenue from personal protective equipment manufacturing and distribution for the nine months ended March 31, 2022, was HKD 7,698,000, down from HKD 38,516,000 in the previous year, indicating a decline of 80.0%[10] - The personal protective equipment business continued to support revenue during the fifth wave of the COVID-19 pandemic in Hong Kong[25] Costs and Expenses - Total service costs for the three months ended March 31, 2022, were HKD 21,220,000, a significant increase from HKD 330,000 in the same period last year[16] - The cost of goods sold for the nine months ended March 31, 2022, was HKD 6,537,000, down from HKD 43,303,000 in the previous year, reflecting a decrease of 84.9%[16] - Sales and distribution expenses, along with administrative and operating expenses, amounted to HKD 34,700,000, a decrease of 24% from HKD 45,400,000 in 2021[24] Shareholder Information - The company has a total of 705,040,364 shares held by major shareholders, representing approximately 15.54% of the issued shares[37] - Integrated Asset Management (Asia) Limited holds 542,363,000 shares, accounting for 11.95% of the total[37] - Major shareholders include Guoyao Pharmaceutical Overseas Holdings Limited, which holds 650,000,000 shares, representing 14.32%[37] - The company has a total of 697,364,364 shares owned by a major shareholder, with 99.89% held by Ms. Zhang and Mr. Chen[41] Convertible Bonds and Stock Options - The company issued convertible bonds with a total value of HKD 89,625,000, which can be converted into a maximum of 249,651,810 shares at a conversion price of HKD 0.359 per share[41] - The conversion price of the convertible bonds was revised to HKD 0.221 per share, allowing for a maximum conversion into 405,542,986 shares[42] - The company plans to negotiate with bondholders regarding the renewal or further extension of the convertible bonds[43] - The stock option plan adopted on January 31, 2013, allows the board to grant options to eligible participants for a period of ten years[45] - The company has issued 4,000,000 stock options to a major shareholder as part of its stock option plan[41] - The total number of options granted under the old share option plan as of March 31, 2022, was 179,750,000, with 600,000 options expired[48] - Under the new share option plan, a total of 77,000,000 options were granted as of March 31, 2022[51] - The exercise price for the options granted was set at HKD 0.25 and HKD 0.33 for different plans[51] - The total number of options available for employees under the old plan was 66,550,000[48] Corporate Governance - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules Appendix 15, with some deviations noted[56] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited results for the nine months ended March 31, 2022, and confirmed compliance with applicable accounting standards[60] - The roles of the chairman and CEO are held by the same individual, which the board believes is beneficial for the company's business prospects and management[56] - The company has established a code of conduct for securities trading by directors, confirming compliance with the required standards during the nine months ended March 31, 2022[59] - Non-executive and independent non-executive directors do not have a fixed term but must retire and seek re-election at least every three years[57] - The company has no interests in any business that directly or indirectly competes with its operations as of March 31, 2022[54] - The audit committee is responsible for reviewing the company's annual reports, interim reports, and quarterly reports, providing recommendations to the board[60] - The board will review the need to appoint a suitable individual as CEO if necessary, given the current dual role of the chairman and CEO[56] - The company is committed to regularly reviewing and updating its corporate governance practices to comply with GEM Listing Rules[57] Other Information - The company did not recognize any taxable profits during the period, resulting in no provision for Hong Kong profits tax[13] - The company reported a net foreign exchange gain of HKD 7,000 for the nine months ended March 31, 2022, compared to a gain of HKD 13,000 in the previous year[16] - The total equity attributable to equity holders as of March 31, 2022, was HKD (129,663,000), compared to HKD (140,556,000) as of March 31, 2021, indicating an improvement of 7.8%[19] - The company recognized share-based payment expenses of HKD 3,917,000 for the nine months ended March 31, 2022, compared to HKD 3,716,000 in the previous year, reflecting a slight increase of 5.4%[19] - The company’s total reserves as of March 31, 2022, were HKD 1,484,000, compared to HKD 1,484,000 as of March 31, 2021, remaining unchanged[19] - No dividend was recommended for the nine months ending March 31, 2022[29] - The group signed a cooperation agreement with a company in Zhejiang Province in March 2022 for the procurement of innovative anti-counterfeiting products[25] - The innovative anti-counterfeiting products incorporate patented technology and aim to enhance brand protection and corporate social responsibility[27] - The group plans to explore applications of innovative anti-counterfeiting products in the digital collectibles market[28] - The group was included in a 24-month standing agreement with the Hong Kong SAR Government's Logistics Services Department in March 2022[27] - The company has not reported any new product or technology developments in the provided content[49] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending March 31, 2022[53]

Financial Performance - Revenue for the six months ended December 31, 2021, was HKD 11,730,000, compared to HKD 55,200,000 for the same period in 2020, representing a decrease of 78.8%[3] - Gross profit for the six months ended December 31, 2021, was HKD 2,593,000, down from HKD 19,552,000 in 2020, a decline of 86.7%[3] - Operating loss for the six months ended December 31, 2021, was HKD 4,306,000, compared to a loss of HKD 4,612,000 for the same period in 2020, indicating a slight improvement[3] - The company reported a net loss of HKD 13,377,000 for the six months ended December 31, 2021, compared to a loss of HKD 14,627,000 in 2020, reflecting a 8.6% improvement[3] - The company reported a net loss of HKD 13,503,000 for the six months ended December 31, 2021, compared to a loss of HKD 14,140,000 for the same period in 2020, indicating a decrease in loss of approximately 4.5%[11] - The company reported a loss before tax of HKD 13,377,000 for the six months ended December 31, 2021, compared to a loss of HKD 14,627,000 in the same period of 2020[25] - The company reported a loss attributable to ordinary shareholders of HKD 4,108,000 for the three months ended December 31, 2021, compared to a loss of HKD 9,505,000 for the same period in 2020, representing a 56.7% improvement[28] - For the six months ended December 31, 2021, the loss attributable to ordinary shareholders was HKD 13,503,000, a decrease of 4.5% from HKD 14,140,000 in the prior year[28] Assets and Liabilities - Total assets as of December 31, 2021, were HKD 144,443,000, down from HKD 135,974,000 as of June 30, 2021[7] - Current liabilities decreased to HKD 214,569,000 as of December 31, 2021, from HKD 272,877,000 as of June 30, 2021, a reduction of 21.4%[7] - The company’s total equity attributable to shareholders decreased to HKD (120,742,000) as of December 31, 2021, from HKD (73,080,000) a year earlier, indicating a decline in shareholder equity[11] - Total liabilities as of December 31, 2021, were HKD 265,300,000, a decrease from HKD 276,459,000 as of June 30, 2021[18] - Trade receivables increased to HKD 104,711,000 as of December 31, 2021, from HKD 93,767,000 as of June 30, 2021, reflecting an increase of 11.5%[30] - Other receivables and prepayments rose to HKD 63,641,000 from HKD 56,448,000, marking a 12.3% increase[30] - The total trade and other receivables amounted to HKD 168,352,000, up from HKD 150,215,000, indicating an increase of 12.1%[30] - The company reported a provision for bad debts of HKD 109,049,000, slightly down from HKD 112,799,000, showing a reduction of 3.3%[30] - Trade payables decreased to HKD 39,797,000 as of December 31, 2021, from HKD 41,513,000 as of June 30, 2021, a decline of 4.1%[32] Cash Flow and Financing Activities - Cash used in operating activities was HKD 39,236,000 for the six months ended December 31, 2021, compared to HKD 5,692,000 for the same period in 2020, reflecting a significant increase in cash outflow[13] - The company recorded a net cash inflow from financing activities of HKD 36,288,000 for the six months ended December 31, 2021, compared to HKD 6,767,000 in the previous year, showing a substantial increase in financing[13] - The company’s cash and cash equivalents were HKD 4,015,000 as of December 31, 2021, down from HKD 7,482,000 as of June 30, 2021[7] - The company’s cash and bank balances were HKD 4,000,000, down from HKD 7,500,000 on June 30, 2021, with current assets increasing to HKD 68,500,000[63] - The company issued convertible bonds amounting to HKD 50,000,000 during the financing activities, which was a new financing strategy implemented in the current period[13] - The company issued convertible bonds with a principal amount of HKD 50,000,000, maturing on February 21, 2023, with an annual interest rate of 7%[40] - The company issued convertible bonds totaling HKD 100,000,000 with a maturity of 18 months and an annual interest rate of 7%[81] - The net proceeds from the issuance of the convertible bonds are intended to be used for various purposes, including approximately HKD 35,000,000 for developing anti-counterfeiting business and HKD 20,000,000 for repaying loans[84] Operational Highlights - The company reported an increase in other income and gains to HKD 15,265,000 for the six months ended December 31, 2021, compared to HKD 2,065,000 in 2020[3] - The cost of services for the six months ended December 31, 2021, was HKD 6,216,000, significantly higher than HKD 1,284,000 in the same period of 2020[25] - The company generated HKD 8,680,000 from the sale of subsidiaries during the six months ended December 31, 2021[20] - The company confirmed equity-settled share-based payments of HKD 3,394,000 during the reporting period, compared to HKD 2,676,000 in the previous year, reflecting an increase in share-based compensation[11] - The company aims to leverage existing sales resources and integrate customer resources to expand its distribution network and capture more revenue in the future[59] - The company plans to maintain its current operational strategy for personal protective equipment while implementing cost control measures[61] Shareholder and Corporate Governance - The board of directors did not recommend the payment of dividends for the six months ending December 31, 2021[62] - The company has adopted a stock option plan since January 31, 2013, to incentivize eligible participants, which was terminated on June 9, 2021[103] - The company has established an audit committee responsible for reviewing financial reports and risk management systems[122] - The chairman and CEO roles are held by the same individual, which the board believes benefits the company's business prospects and management[120] - The company has not reported any options exercised or canceled under the new share option plan as of the reporting date[108] - The company has received written consent from Integrated Asset for the extension of the convertible bonds' maturity date[98] Market and Industry Insights - Lottery-related services recorded HKD 800,000, a decrease of 66% compared to the same period in 2020, with a gross profit of HKD 700,000 and a gross margin of 92%[48] - The "Internet+" service business saw revenues of HKD 400,000 and HKD 6,100,000 from solution services and supply chain services, respectively, down 71% year-on-year, with a gross profit of HKD 300,000 and a gross margin of 5%[48] - The manufacturing and distribution of personal protective equipment generated HKD 4,400,000, an 85% decrease from the same period in 2020, with a gross profit of HKD 1,500,000 and a gross margin of 34%[48] - The anti-counterfeiting business has expanded its sales footprint to cover seven industries, including health food, beer, and fruit distribution, with contracts signed across five provinces[53]